Cargando…

Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study

BACKGROUND: Healthcare resource utilisation for Alzheimer’s disease (AD) in China is not well understood. This Delphi panel study aimed to describe the clinical management pathways for moderate and severe AD patients in urban China and to define the amount and cost of healthcare resources used. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xin, Chen, Shengdi, Chen, Xiaochun, Jia, Jianjun, Li, Chunhou, Liu, Cong, Toumi, Mondher, Milea, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546035/ https://www.ncbi.nlm.nih.gov/pubmed/26301090 http://dx.doi.org/10.1186/s40035-015-0038-9

Ejemplares similares

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
por: Clay, Emilie, et al.
Publicado: (2019)

Cost of heart failure management in Turkey: results of a Delphi Panel
por: Aras, Dursun, et al.
Publicado: (2016)

Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs
por: Çavuşoğlu, Yüksel, et al.
Publicado: (2022)

Why “American Patients First” is likely to raise drug prices outside of the United States
por: Dabbous, Monique, et al.
Publicado: (2019)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel
por: Morell, Ferran, et al.
Publicado: (2016)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease
por: Lin, Chung-Hsien, et al.
Publicado: (2019)

Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease
por: Yang, Kuen-Cheh, et al.
Publicado: (2016)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning
por: Ricciardi, Walter, et al.
Publicado: (2015)

Introduction
por: Toumi, Mondher, et al.
Publicado: (2015)

Economic and health implications from earlier detection of HIV infection in the United Kingdom
por: Zah, Vladimir, et al.
Publicado: (2016)

Non-profit drug research and development: the case study of Genethon
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach
por: Sruamsiri, Rosarin, et al.
Publicado: (2017)

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform
por: Chen, Yixi, et al.
Publicado: (2016)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Drugs foresight 2020: a Delphi expert panel study
por: Lintonen, Tomi, et al.
Publicado: (2014)

Teleconsultations for mental health: Recommendations from a Delphi panel
por: Manera, Valeria, et al.
Publicado: (2023)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Gut Microbiota: Implications in Alzheimer’s Disease
por: He, Yixi, et al.
Publicado: (2020)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Characteristics of doctor-shoppers: a systematic literature review
por: Biernikiewicz, Małgorzata, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5emrbag1uja7t9g3b14fs7q5p1